Indian drug regulator allows Cadila Healthcare to conduct phase III trials for two-dose COVID-19 vaccine

The company has already received the emergency use authorization from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses

Press Trust of India October 05, 2021 17:38:05 IST
Indian drug regulator allows Cadila Healthcare to conduct phase III trials for two-dose COVID-19 vaccine

New Delhi: Drug firm Cadila Healthcare on Tuesday said it has received permission from the Indian drug regulator for conducting phase III trials for its two-dose COVID-19 vaccine ZyCoV-D.

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20.

The company has "... got the permission for conduct of phase III trials for two-dose Covid vaccine," Cadila Healthcare said in a regulatory filing.

Earlier in August, in a filing to BSE, Cadila Healthcare had said that it plans to seek approval for the two dose regimen of the vaccine. It had also mentioned that the company plans to manufacture 10-12 crore doses of ZyCoV-D annually.

Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.

Updated Date:

also read

WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months
India

WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months

The UN body has also sought a meeting with the Drugs Controller General of India to discuss the matter 10:12

Biocon gets DCGI nod for emergency use of CytoSorb to treat critical COVID-19 patients
Business

Biocon gets DCGI nod for emergency use of CytoSorb to treat critical COVID-19 patients

Biotechnology major Biocon on Wednesday said its subsidiary has received approval from the Drugs Controller General of India (DCGI) for a medical device to treat critical COVID-19 patients

Bharat Biotech gets nod for India's first nasal COVID vaccine: Why this is a potential game-changer
Explainers

Bharat Biotech gets nod for India's first nasal COVID vaccine: Why this is a potential game-changer

Bharat Biotech says the vaccine is easy to administer as it is non-invasive and does not require trained healthcare workers. It also eliminates needle-associated risks such as injuries and infections and is scalable when it comes to manufacturing